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Abstract
Background: It is well established that estrogens and other hormonal factors influence breast cancer susceptibility.
We hypothesized that a woman’s total lifetime estrogen exposure accumulates changes in DNA methylation,
detectable in the blood, which could be used in risk assessment for breast cancer.
Methods: An estimated lifetime estrogen exposure (ELEE) model was defined using epidemiological data from
EPIC-Italy (n = 31,864). An epigenome-wide association study (EWAS) of ELEE was performed using existing Illumina
HumanMethylation450K Beadchip (HM450K) methylation data obtained from EPIC-Italy blood DNA samples
(n = 216). A methylation index (MI) of ELEE based on 31 CpG sites was developed using HM450K data from EPIC-
Italy and the Generations Study and evaluated for association with breast cancer risk in an independent dataset
from the Generations Study (n = 440 incident breast cancer cases matched to 440 healthy controls) using targeted
bisulfite sequencing. Lastly, a meta-analysis was conducted including three additional cohorts, consisting of 1187
case-control pairs.
Results: We observed an estimated 5% increase in breast cancer risk per 1-year longer ELEE (OR = 1.05, 95% CI 1.04–1.07,
P = 3× 10−12) in EPIC-Italy. The EWAS identified 694 CpG sites associated with ELEE (FDR Q < 0.05). We report a DNA
methylation index (MI) associated with breast cancer risk that is validated in the Generations Study targeted bisulfite
sequencing data (ORQ4_vs_Q1 = 1.77, 95% CI 1.07–2.93, P = 0.027) and in the meta-analysis (ORQ4_vs_Q1 = 1.43, 95% CI 1.05–
2.00, P = 0.024); however, the correlation between the MI and ELEE was not validated across study cohorts.
Conclusion: We have identified a blood DNA methylation signature associated with breast cancer risk in this study. Further
investigation is required to confirm the interaction between estrogen exposure and DNA methylation in the blood.
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Background
Breast cancer is the most common women’s cancer, with
an estimated 1.67 million cases diagnosed globally in 2012
[1]. Its crude incidence is rising due to an aging popula-
tion and population-level changes in reproductive and life-
style factors that affect breast cancer risk [2]. Up to 23% of
breast cancer cases are considered preventable by lifestyle
changes, such as maintaining a healthy weight and redu-
cing alcohol consumption [3]. There is a need for
improved risk assessment methods to target prevention
and early detection to women at increased risk.
It is well established that estrogens play a role in
breast cancer etiology, and women with higher circulat-
ing estrogen concentrations have an increased risk of
breast cancer [4–6]. Several hormonal breast cancer risk
factors contribute to a woman’s lifetime estrogen expos-
ure. These include a younger age at menarche and an
older age at menopause, which together define the re-
productive span during which a woman is exposed to
high levels of endogenous estrogens produced by the
ovaries [7, 8]. The number of pregnancies is associated
with a long-term decrease in both estrogen exposures
and breast cancer risk [9, 10]. A small decrease in risk is
seen for women who breastfeed for longer, and this de-
creases the total lifetime estrogen exposure [11, 12]. Ex-
ogenous hormones provided by oral contraceptives (OC)
and hormone replacement therapy (HRT) increase risk
during use, but risk returns to that for unexposed
women 5–10 years after cessation [13–17]. Additionally,
lifestyle risk factors for breast cancer such as higher
postmenopausal body mass index (BMI), alcohol con-
sumption, physical inactivity, and smoking can each
affect circulating estrogen concentrations [4, 18–22].
Epigenetic mechanisms such as DNA methylation control
gene expression and may be influenced by environmental
and lifestyle exposures. Epigenome-wide association studies
(EWAS) of blood DNA methylation for breast cancer risk
measured have identified associations with global hypome-
thylation and several candidate genes, but these have gener-
ally not been replicated across studies [23–26]. Numerous
large EWAS have identified epigenetic signatures for smok-
ing [27], alcohol consumption [28], BMI [29], and aging [30,
31], and hypomethylation signatures associated with smok-
ing can improve the prediction of lung cancer [32, 33]. We
propose that an EWAS of breast cancer risk factors may
identify CpG sites that could be used in risk prediction
models [23]. We hypothesize that estrogen exposures over
the lifetime give rise to accumulated changes in DNA
methylation, detectable in the blood, which might add useful
information to breast cancer risk prediction.
The aims of this study were to identify a DNA methyla-
tion signature reflecting a woman’s lifetime estrogen expos-
ure and assess the signatures’ association with breast cancer
risk. There is no standard model to estimate a woman’s
total lifetime estrogen exposure, and numerous approaches
have been used [34–39]. For example, the Pike model
reflecting the “breast tissue aging” in relation to breast can-
cer risk includes a woman’s age at menarche, age at first
full-term pregnancy, and age at menopause modeling
changes over time [38]. In this study, we have used an esti-
mated lifetime estrogen exposure (ELEE) model that re-
flects the reproductive span, comprising a woman’s time
between age at menarche and age at menopause minus 1
year for each pregnancy and duration of breastfeeding, cal-
culated at the time at recruitment. We performed an
EWAS and identified 694 CpG sites associated with ELEE.
We then developed a methylation signature of ELEE that
showed association with breast cancer risk and was further
validated in a large independent study cohort using targeted
bisulfite sequencing, and a meta-analysis of three additional
independent study cohorts.
Methods
Study cohorts
Data from two independent prospective cohort studies
were used for the primary analysis: the Italian cohort
from the European Prospective Investigation into Cancer
and Nutrition study (EPIC-Italy) and the UK-based Gen-
erations Study. Questionnaire data and blood samples
were collected at the time of study enrollment.
EPIC-Italy included epidemiological questionnaire data
from 32,059 women (dataset 1) and peripheral blood
DNA methylation data measured using the HM450K
array for 162 matched pairs of incident breast cancer
cases and controls (dataset 2) [24]. The Generations
Study cohort included HM450K peripheral blood DNA
array data for a subset of 92 healthy women (dataset 3)
[40] and 440 matched pairs of incident breast cancer
cases and controls (independent from the HM450K
dataset), who provided blood DNA samples used for tar-
geted bisulfite sequencing (dataset 4). Inclusion criteria
for incident breast cancer cases in the Generations
Study, with blood samples taken prior to diagnosis, were
the following: invasive ER-positive breast cancer with no
previous history of (non-breast) cancer, white ethnicity,
and completeness of epidemiological data. Controls were
individually matched to cases on age at blood draw ± 5
years. Additional replication cohorts used in the
meta-analysis included an additional 118 case-control
pairs from EPIC-Italy (dataset 5), 435 case-control pairs
from EPIC-IARC (dataset 6) [41], and 310 case-control
pairs from the MCCS (dataset 7) [42]. Further information
for these study cohorts is provided in Additional file 1:
Supplementary material and methods.
EWAS of ELEE
Different ELEE models including a woman’s reproduct-
ive span (age at menopause minus age at menarche for
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postmenopausal women and age at recruitment minus
age at menarche for premenopausal women), number of
pregnancies, and breastfeeding duration were consid-
ered. The models were assessed for association with
breast cancer risk in EPIC-Italy (n = 1193 cases and
30,671 controls, Additional file 2: Table S1) using
age-adjusted Cox regression. The ELEE model selected
for the EWAS included as many of these risk factors as
possible without reducing the significance of the associ-
ation with breast cancer for pre- and postmenopausal
women. An EWAS with ELEE as the exposure and DNA
methylation as the outcome was conducted for EPIC-
Italy using a beta regression model on HM450K beta
values. Subjects with missing information for ELEE were
excluded (n = 87), as were cases with age at diagnosis < 50
(n = 28), to enrich for ER-positive disease, leaving 216
women for the EWAS (Additional file 2: Table S2). Poten-
tial confounders, known to influence methylation or estro-
gen levels, were adjusted for; these included age, BMI,
alcohol consumption, and smoking duration, all reported
at recruitment, as well as technical confounders including
batch, position on batch, and white blood cell (WBC)
composition [43]. Multiple testing was accounted for
using the false discovery rate (FDR) Q values in R function
“p.adjust.” Beta regression coefficients are not interpret-
able as methylation percentage changes. Therefore, to get
interpretable estimates for the significantly associated
CpG sites, i.e., percentage change in DNA methylation per
unit longer ELEE, a linear mixed-effects regression model
adjusted for the same variables, including random effects
for batch and position on chip, was applied to beta values
multiplied by 100.
Laboratory analysis
HM450K array data generation has been described pre-
viously [24, 40–42]. For validation, targeted bisulfite se-
quencing was conducted in the Generations Study
(n = 880) using the Fluidigm 48.48 Access Array.
Forty-two CpG sites for validation were selected from
the EWAS based on the magnitude of change in DNA
methylation (> 0.1%) per 1-year longer ELEE (mixed-ef-
fects linear regression model coefficient) and statistical
significance of association with ELEE (beta regression
model P value < 7 × 10−5). To estimate WBC compos-
ition, five HM450K CpG probes that showed independ-
ent correlation with five different WBC types were
included in the target panel (Additional file 3: Figure
S1). The 880 Generations Study samples were sequenced
on the Illumina MiSeq in 20 batches in four sequencing
pools (6, 5, 5, and 4 batches). After quality control, two
batches were rerun (batches 12 and 19) due to poor se-
quencing data, likely a result of decreased performance
for the barcodes used for these batches. In the results,
only the sequencing data from the new batches 12 and
19 are used, referring to sequencing pool 5. DNA methy-
lation levels were extracted using Bismark [44] and ana-
lyzed in R version 3.3.2.
Statistical analysis
Quality control (QC) of the targeted sequencing data
was conducted to exclude CpG sites (n = 42) with low
coverage or with large difference in DNA methylation
levels between duplicated pairs (n = 31 CpG sites passing
quality control). A methylation index (MI) of ELEE was
developed using the same 31 CpG sites in the HM450K
data with complete information for ELEE from both
EPIC-Italy (dataset 2, n = 237) and the Generations
Study (dataset 3, n = 65, Additional file 2: Table S2). To
develop the MI, ridge regression was conducted in a
10-fold cross-validation repeated 100 times, using the R
package “glmnet” in “train” in the R package “caret” to
estimate the following parameters: penalty coefficient
(lambda) for ridge regression and regression coefficients
for the model. The final MI model for predicted ELEE
was calculated as a linear function, i.e., intercept plus
the sum of the DNA methylation levels at the CpG sites
included in the model weighted by their coefficient. The
correlation between the MI and ELEE was evaluated in
the Generations Study targeted sequencing data (dataset
4, pairs with coverage > 30 sequence reads for at least
10% of the remaining CpG sites) using the Pearson’s cor-
relation coefficient. The association between the MI and
risk of breast cancer was assessed using conditional lo-
gistic regression (R function “clogit” in the package
“survival”) for matched case-control pairs in EPIC-Italy
HM450K development data (dataset 2, n = 162 pairs),
the Generations Study targeted sequencing validation
data (dataset 4), and in each of the additional cohorts for
the meta-analysis including EPIC-Italy (dataset 5, n = 118
pairs), EPIC-IARC (dataset 6, n = 420 pairs), and MCCS
(dataset 7, n = 310 pairs). The meta-analysis of log odds ra-
tios and standard errors was conducted using a weighted
random-effects model, applying the restricted-maximum
likelihood method (function “rma.uni” in the R package
“metafor”). The Cochran’s Q statistics and I2 statistics were
used to estimate heterogeneity between the studies;
Q < 0.05 and I2 > 50% were defined as heterogeneous esti-
mations. If the heterogeneity I2 was equal to 0, the
meta-analysis behaved as a fixed-effects model. The ORs
for all models were adjusted for baseline age, BMI, alcohol
consumption, smoking duration, and estimated WBC com-
position in a multivariable model. Additionally, for each of
the target CpG sites passing QC, the association with breast
cancer risk was investigated using conditional logistic re-
gression. Further details on methods and workflow are de-
scribed in Additional file 1: Supplementary material and
methods and Additional file 3: Figure S2.
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Results
The ELEE is associated with breast cancer risk in EPIC-Italy
The estimated lifetime estrogen exposure (ELEE) was
calculated as a woman’s reproductive span (age at meno-
pause or, for premenopausal women, age at recruitment,
minus age at menarche) minus 1 year per pregnancy and
breastfeeding duration before recruitment in years. For
EPIC-Italy (dataset 1, n = 1193 cases and 30,671 controls,
Additional file 2: Table S1), a 1-year longer ELEE, ran-
ging from 5 to 49, was associated with a 5% increase in
breast cancer risk (hazard ratio (HR) = 1.05, 95% confi-
dence interval (CI) 1.04–1.07, P = 3 × 10−12, Additional
file 2: Table S3) and was associated with breast cancer
risk for both pre- and postmenopausal women
(HR = 1.09, 95% CI 1.03–1.15, P = 0.002, and HR = 1.03,
95% CI 1.01–1.05, P = 6 × 10−4, Additional file 2: Table S3).
EWAS identifies CpG sites associated with ELEE in EPIC-
Italy
The EWAS of ELEE conducted in EPIC-Italy (dataset 2,
n = 216, Additional file 2: Table S2) gave P values that
were moderately inflated (Additional file 3: Figure S3),
with a genomic inflation factor lambda of 1.13. After
correction for multiple testing, the EWAS identified 694
CpG probes associated with ELEE (FDR Q < 0.05, Fig. 1a)
with a mix of hypo- and hypermethylated CpG probes
(Fig. 1b). Two sensitivity analyses were conducted firstly,
including all cases and controls with complete informa-
tion of ELEE (n = 237), and secondly for controls only
(n = 119), and estimates from each analysis were highly
correlated (r = 0.997 and r = 0.963, respectively,
Additional file 3: Figure S4). All CpG probes were asso-
ciated with ELEE (Q < 0.05) in the first analysis and 563
in the second analysis with controls only. Out of the 694
CpG probes associated with ELEE, CpG sites were se-
lected for the targeted bisulfite sequencing. The selection
was based on the largest magnitude of change in DNA
methylation (> 0.1%) and statistical significance (P < 7 ×
10−5). Furthermore, poorly performing assays were ex-
cluded before the sequencing in the Generations Study. A
total of 42 CpG sites were included in the final target
panel for targeted bisulfite sequencing in the Generations
Study using the Fluidigm 48.48 Access Array (Table 1).
Quality control of targeted sequencing data prior to
model development
Targeted bisulfite sequencing of 42 target regions using
the Fluidigm 48.48 Access Array was conducted for 880
samples (440 matched case-control pairs) from the Gen-
erations Study (dataset 4). The targeted sequencing data
was of high quality: average sequencing depth per CpG
site per sample was 1740, > 97% of the reads were
assigned to a sample (i.e., had a barcode sequence), and
> 99% of the paired reads were aligned to target regions
(Additional file 2: Table S4). Additionally, a high correl-
ation in DNA methylation values was observed between
batches, but with some variability in some of the assays
(mean r = 0.88). Eleven CpG sites were excluded from
the analysis due either to low coverage across batches or
to high variation in DNA methylation levels between du-
plicated pairs. Out of the 880 samples, subjects were ex-
cluded due to incorrect case-control status (1 pair) or
low coverage in > 10% remaining target CpG sites
(n = 100 matched pairs where at least one sample of the
pair had low coverage), leaving a total of 678 samples
(339 matched case-control pairs, Table 2) for the
A B
Fig. 1 EWAS identifies CpG sites significantly associated with ELEE in EPIC-Italy. An EWAS with DNA methylation (HM450K beta values) as
outcome and ELEE as exposure was conducted in EPIC-Italy (n = 216) using a beta regression model adjusted for age, BMI, alcohol consumption,
and smoking duration (all variables reported at recruitment), and batch, position on batch, and WBC composition. a Manhattan plot of minus
log10Q values for FDR-corrected P values from the EWAS of all 404,596 probes across the genome. Blue line indicates FDR Q value threshold of
0.05. b Volcano plot of the regression coefficients (estimates) from the beta regression model, showing significant hypomethylated (in blue) and
hypermethylated probes (in purple)
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Table 1 List of the 42 target CpG sites included in the targeted bisulfite sequencing
HM450K
probe
Chr Position Nearest
gene
Distance
to gene
EWAS of ELEE in EPIC-Italyb
Estimate SE P value Q value
cg01893629 chr12 34494825 ALG10 313588 − 0.14 0.03 8.15E−05 4.96E−02
cg08254089a chr20 36933189 BPI 0 − 0.28 0.08 7.04E−05 4.78E−02
cg21590238 chr12 121454837 C12orf43 536 − 0.29 0.08 2.67E−06 1.44E−02
cg21153102 chr15 41252147 CHAC1 3429 − 0.43 0.14 6.16E−05 4.58E−02
cg03340215a chr15 83315615 CPEB1 0 − 0.31 0.08 4.78E−05 4.21E−02
cg06968859 chr2 80724209 CTNNA2 0 − 0.26 0.05 2.52E−09 1.02E−03
cg12105860a chr12 31742801 DENND5B 0 0.14 0.03 1.58E−06 1.21E−02
cg16840364a chr4 84539569 GPAT3 12541 − 0.14 0.06 4.77E−05 4.21E−02
cg08835688 chr7 50849931 GRB10 0 − 0.14 0.03 4.50E−05 4.11E−02
cg08349826 chr16 10346403 GRIN2A 69791 − 0.11 0.04 4.19E−05 4.02E−02
cg23681866 chr6 29895175 HLA-J 0 − 1.33 0.31 2.17E−05 3.13E−02
cg22968966 chr16 22959875 HS3ST2 32215 − 0.40 0.12 7.95E−05 4.92E−02
cg15127563 chr2 231729487 ITM2C 132 0.36 0.09 1.77E−05 2.95E−02
cg20020161 chr2 231732669 ITM2C 0 − 0.14 0.04 4.49E−05 4.11E−02
cg22097768 chr17 61615913 KCNH6 0 − 0.20 0.05 4.88E−05 4.25E−02
cg17969123 chr19 18745971 KLHL26 1865 − 0.15 0.04 3.18E−05 3.65E−02
cg05422360 chrX 75648455 MAGEE1 0 − 0.44 0.12 1.72E−07 5.26E−03
cg01768446 chr16 89982419 MC1R 1866 − 0.13 0.03 4.57E−05 4.13E−02
cg25372296 chr1 98510328 MIR137HG 0 0.33 0.09 3.83E−06 1.65E−02
cg04519403a chr5 79298951 MTX3 11862 − 0.24 0.05 7.51E−06 2.20E−02
cg12091786 chr20 61877942 NKAIN4 0 − 0.37 0.10 2.07E−05 3.06E−02
cg25279613a chr7 24956523 OSBPL3 0 0.20 0.06 4.95E−06 1.96E−02
cg24536703 chr11 77183438 PAK1 0 − 0.32 0.09 2.71E−05 3.43E−02
cg24036523 chr14 73712256 PAPLN 0 − 0.45 0.11 3.05E−05 3.65E−02
cg16720405 chr3 122790178 PDIA5 0 − 0.17 0.05 5.17E−05 4.33E−02
cg13674411 chr1 204232677 PLEKHA6 0 0.11 0.03 3.50E−05 3.76E−02
cg20684174 chr11 7541255 PPFIBP2 0 − 0.13 0.03 1.23E−05 2.67E−02
cg01430588a chr17 56769767 RAD51C 194 − 0.32 0.09 6.04E−05 4.51E−02
cg22273487 chr20 32580931 RALY 525 0.19 0.05 1.60E−05 2.84E−02
cg22343083 chr8 54786401 RGS20 0 − 0.30 0.07 1.92E−06 1.26E−02
cg22758104 chr17 50465 RPH3AL 11713 − 0.23 0.06 4.62E−07 6.07E−03
cg16733643a chr1 41575522 SCMH1 0 − 0.42 0.11 5.00E−05 4.25E−02
cg17588491 chr22 25198892 SGSM1 3242 − 0.17 0.04 4.41E−05 4.06E−02
cg13971030 chr11 35366721 SLC1A2 0 − 0.49 0.14 9.19E−06 2.41E−02
cg17567562a chr3 47687980 SMARCC1 0 − 0.48 0.11 1.18E−05 2.66E−02
cg10298859 chr13 112883993 SPACA7 146656 − 0.20 0.04 2.26E−07 5.26E−03
cg19216791 chr19 5568216 TINCR 210 − 0.25 0.07 4.13E−05 4.02E−02
cg25936380 chr2 120981591 TMEM185B 606 − 0.29 0.07 2.22E−07 5.26E−03
cg01824466a chr8 95959531 TP53INP1 0 − 0.23 0.08 8.08E−05 4.96E−02
cg26657235 chr6 150378972 ULBP3 4367 − 0.12 0.03 1.32E−05 2.76E−02
cg08551047 chr15 91473569 UNC45A 0 − 0.58 0.14 2.87E−06 1.46E−02
cg20394620a chrX 48541924 WAS 260 − 0.20 0.05 3.02E−06 1.46E−02
SE standard error
aMarked probes did not pass quality control in the targeted sequencing data and were not included in the analysis of the methylation index
bResult from the EWAS of ELEE in EPIC-Italy (n = 216, dataset 2). The estimates correspond to regression coefficients from a mixed-effects linear regression
model (percentage change in DNA methylation per unit longer ELEE), and P values from the beta regression model, which have been corrected for
multiple testing using FDR (Q values)
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analyses. In the 328 matched case-control pairs in the Gen-
erations Study with coverage > 30 for all five WBC CpG
sites, no difference (P > 0.05) in DNA methylation levels be-
tween cases and controls were observed (Additional file 3:
Figure S1).
The MI is associated with breast cancer risk
A methylation index (MI) to predict ELEE was devel-
oped in HM450K data from EPIC-Italy (dataset 2,
n = 237) and the Generations Study (dataset 3, n = 65,
Additional file 2: Table S2) using ridge regression on the
31 target CpG sites passing QC in the targeted bisulfite
sequencing data. As expected, the MI correlated with
ELEE in the development data; a high correlation was
observed in EPIC-Italy (r = 0.60, P = 6 × 10−25) and mod-
erately correlated in the Generations Study HM450K
data (r = 0.27, P = 0.027, Fig. 2a). The correlation be-
tween the MI and ELEE, however, was not replicated in
the Generations Study targeted sequencing data
(n = 678, r = − 0.04, P = 0.340, Fig. 2b). We also observed
no association between the ELEE and breast cancer risk
in the Generations Study (n = 339 matched case-control
pairs, age-adjusted odds ratio (OR) = 1.01, 95% CI 0.98–
1.04, P = 0.562), in contrast to EPIC-Italy subjects from
the HM450K dataset (n = 162 matched case-control
pairs, age-adjusted OR = 1.10, 95% CI 1.03–1.17,
P = 0.007). The correlations between the MI and ELEE
were similar for pre- and postmenopausal women in the
Generations Study, but stronger for postmenopausal
women (r = 0.72, P = 2 × 10−22) than for premenopausal
women (r = 0.53, P = 7 × 10−7) in EPIC-Italy (test for het-
erogeneity between pre- and postmenopausal women in
EPIC-Italy: Q = 0.79, I2 = 0 (no heterogeneity); Genera-
tions Study: Q = 0.42, I2 = 0 (no heterogeneity)).
The association between the MI and breast cancer risk
was tested using matched case-control pairs from
EPIC-Italy HM450K data and the Generations Study tar-
geted sequencing data (n = 162 and 339 pairs respect-
ively, Table 2). In a multivariable model, each unit
increase in the MI, ranging from 27.6 to 39.1, was asso-
ciated with a 51% increase in breast cancer risk in
EPIC-Italy (OR = 1.51, 95% CI 1.28–1.82, P = 1 × 10−5,
Fig. 2c). The association was validated in the Genera-
tions Study targeted sequencing data: A comparable
Table 2 Table of characteristics for case-control pairs in EPIC-Italy and the Generations Study
EPIC-Italy The Generations Study
Cases (n = 162) Controls (n = 162) Cases (n = 339) Controls (n = 339) Pb
Age Mean (st.dev.), years 52.9 (7.2) 53.0 (7.1) 53.9 (10.3) 54.1 (10.4) 0.054
Time to diagnosis Mean (st.dev.), years 5.3 (4.4) NA 4.0 (2.4) NA 0.022
Menopausal status n (%) 0.690
Premenopausal 52 (32.1%) 49 (30.2%) 135 (39.8%) 127 (37.5%)
Postmenopausal 85 (52.5%) 87 (53.7%) 204 (60.2%) 212 (62.5%)
Age at menarche Mean (st.dev.), years 12.7 (1.4) 12.7 (1.7) 12.7 (1.4) 12.7 (1.5) 0.914
Age at menopause Mean (st.dev.), years 50.2 (3.7) 49.1 (3.8) 50.3 (4.3) 50.1 (4.5) 0.126
Number of pregnancies Mean (st.dev.) 1.6 (1.1) 1.7 (1.0) 1.9 (1.1) 1.9 (1.2) 4 × 10−4
Ever breastfed n (%) 103 (63.6%) 112 (69.1%) 265 (78.2%) 274 (80.8%) 0.179
Breastfeeding duration Mean (st.dev.), years 0.7 (0.6) 0.8 (0.7) 0.9 (1.0) 0.8 (0.9) 2 × 10−5
BMI Mean (st.dev.), kg/m2 25.8 (4.1) 25.3 (4.3) 25.7 (4.3) 25.2 (4.3) 0.626
Alcohol consumptiona Mean (st.dev.) 5.5 (7.0) 7.4 (9.9) 15.8 (16.7) 14.6 (15.5) 2 × 10−26
Smoking status n (%) 8 × 10−10
Smoker 31 (19.1%) 36 (22.2%) 25 (7.4%) 23 (6.8%)
Former 23 (14.2%) 41 (25.3%) 98 (28.9%) 86 (25.4%)
Never 106 (65.4%) 85 (52.5%) 216 (63.7%) 230 (67.9%)
Smoking duration Mean (st.dev.), years 8.1 (12.6) 10.6 (13.4) 4.4 (9.0) 3.9 (9.0) 4 × 10−10
OC ever n (%) 59 (36.4 %) 67 (41.4 %) 253 (74.6%) 256 (75.5%) < 2 × 10−16
OC duration Mean (st.dev.), years 4.1 (5.1) 5.6 (5.8) 8.1 (6.4) 8.8 (6.8) 4 × 10−9
HRT ever n (%) 23 (14.2 %) 28 (17.3 %) 239 (70.5%) 241 (71.1%) 2 × 10−7
HRT duration Mean (st.dev.), years 2.8 (2.7) 2.6 (3.4) 6.7 (5.7) 5.4 (4.3) 5 × 10−8
aAlcohol consumption in the Generations Study reported in average units per week, converted to average gram per day by multiplying with 8 (1 unit = 8 g
alcohol) and dividing by 7
bP values indicate differences between all subjects from EPIC-Italy and all subjects from the Generations Study: t test for continuous variables, chi-squared test for
categorical variables
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analysis of the Generations Study data gave an estimated
4% increase in risk per unit increase in MI, which ranged
from 20.3 to 53.1 (OR = 1.04, 95% CI 1.01–1.08, P = 0.022,
Fig. 2d). The OR estimate was greater for postmenopausal
women in both EPIC-Italy and the Generations Study
(OR = 1.91, 95% CI 1.29–2.82, P = 0.001 and OR = 1.07,
95% CI 1.02–1.12, P = 0.006, respectively) than for pre-
menopausal women (OR = 1.61, 95% CI 1.17–2.22,
P = 0.004 and OR = 1.01, 95% CI 0.94–1.09, P = 0.713, re-
spectively). However, the test for heterogeneity between
pre- and postmenopausal women in EPIC-Italy, Q = 0.19
and I2 = 43, and Generations Study, Q = 0.24 and I2 = 27,
suggested no significant heterogeneity.
Sensitivity analysis on the model development was also
conducted using controls only in the combined EPIC-Italy
and the Generations Study HM450K data (datasets 2 and
3, n = 184). The control-only MI model showed a very
similar association with breast cancer risk as previously
when tested on the case-control pairs from the Genera-
tions Study (n = 339 pairs, OR = 1.04 per unit increase in
MI, 95% CI 1.01–1.08, P = 0.012).
Meta-analysis of the association between MI and breast
cancer risk
The association between the MI and breast cancer risk
was examined in a meta-analysis, excluding the discovery
data from EPIC-Italy. The analysis included 2374 women
(1187 matched case-control pairs) from four prospective
study cohorts, the Generations Study targeted sequencing
data, additional subjects from EPIC-Italy, EPIC-IARC, and
A B
C D
Fig. 2 The MI is associated with breast cancer risk. The MI was developed in combined HM450K data from EPIC-Italy (dataset 2, n = 237) and the
Generations Study (dataset 3, n = 65) using ridge regression. The correlation between the MI and ELEE and the association between the MI and
breast cancer risk were evaluated. a The correlations between the MI and ELEE in the development of HM450K data were as follows: r = 0.60 and
P = 6 × 10−25 for EPIC-Italy and r = 0.27 and P = 0.027 for the Generations Study b The MI and ELEE were not correlated in the Generations Study
targeted sequencing data (r =− 0.04, P = 0.340). c Density plot of the MI values in controls and cases in EPIC-Italy HM450K data. The MI was
significantly associated with breast cancer risk in EPIC-Italy (n = 162 pairs, OR = 1.51, 95% CI 1.26–1.82, P = 1 × 10−5). d Density plot of the MI
values in controls and cases in the Generations Study targeted sequencing data. The MI was significantly associated with breast cancer risk in the
Generations Study (n = 339 pairs, OR = 1.04, 95% CI 1.01–1.08, P = 0.022). ORs were adjusted for age, BMI, alcohol consumption, and smoking
duration (all variables reported at recruitment) and WBC composition
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MCCS, with mean time to diagnosis of 4.0, 8.5, 7.5, and
7.9 years, respectively (Additional file 2: Table S7). All esti-
mates were adjusted for baseline age, BMI, smoking dur-
ation, alcohol consumption, and WBC composition. The
combined meta-analysis for MI as a continuous variable
showed low heterogeneity across study cohorts (Q = 0.45,
I2 = 0%) and an association with breast cancer risk, with
4% increase in risk per one unit increase in the MI
(OR = 1.04, 95% CI 1.00–1.07, P = 0.024, Fig. 3a). Women
in the highest quartile compared with the lowest quartile
of MI had higher breast cancer risk with a combined OR
of 1.45 (OR = 1.45, 95% CI 1.05–2.00, P = 0.024, Fig. 3b)
and low heterogeneity (Q = 0.44, I2 = 16%). There was no
significant association between the MI and breast cancer
risk between pairs with a shorter time to diagnosis (less
than median) in the combined meta-analysis (OR = 1.03,
95% CI 0.98–1.08, P = 0.241), but there was a significant
association in pairs with time to diagnosis above the median
(OR = 1.05, 95% CI 1.01–1.10, P= 0.021) (Additional file 2:
Table S8). Lastly, the MI did not correlate with the ELEE in
any of these four study cohorts (Additional file 2: Table S9).
To explore non-linearity in the association between
the MI and breast cancer risk, the MI was stratified into
quartiles defined by the distribution in controls in each
cohort. A higher breast cancer risk was observed for
women in the highest quartile compared with those in
the lowest quartile in EPIC-Italy (ORQ4_vs_Q1 = 5.45, 95%
CI 2.17–13.67, P = 3 × 10−4) and in the Generations
Study (ORQ4_vs_Q1 = 1.77, 95% CI 1.07–2.93, P = 0.027,
Additional file 2: Table S5), but not in three additional
cohorts. In the meta-analysis, excluding the EPIC-Italy
development data, increased breast cancer risk was ob-
served for women in the highest quartile compared with
the lowest quartile (OR = 1.45, 95% CI 1.05–2.00,
P = 0.024) and modest heterogeneity (Q = 0.44; I2 = 16%,
Additional file 2: Table S5).
Reverse causation would be indicated if the associ-
ation between MI and breast cancer risk was higher
in cases with a short time to diagnosis. To explore
this, we investigated the association between the MI
and breast cancer risk stratified by median time to
diagnosis in cases. In the EPIC-Italy development
data, and in the meta-analysis, the association be-
tween the MI and breast cancer risk appeared to be
stronger with longer time to diagnosis. In EPIC-Italy,
the association between the MI and breast cancer risk
was significant for both groups but with a higher OR
for pairs with a longer time to diagnosis (n = 81 pairs
in both groups, OR = 1.47, 95% CI 1.12–1.93,
P = 0.005 vs OR = 1.84, 95% CI 1.30–2.61, P = 0.001;
Fig. 4a, b). In the meta-analysis, for pairs with shorter
time to diagnosis, there was no significant association
with breast cancer risk (n = 721 pairs, OR = 1.03, 95%
CI 0.98–1.08, P = 0.241, Fig. 4c); however, the MI was
associated with breast cancer risk for pairs with a
time to diagnosis above the median (n = 804 pairs,
OR = 1.05, 95% CI 1.01–1.10, P = 0.021, Fig. 4d).
Therefore, the data do not support reverse causation
A
B
Fig. 3 Meta-analysis of the association between MI and breast cancer risk. The association between MI and risk for breast cancer, as a continuous
variable (a) or as a categorical variable (b), was estimated in the four studies included in the meta-analysis using conditional logistic regression
adjusted for age, BMI, alcohol consumption, and smoking duration (all variables reported at recruitment) and WBC composition. The log odds
ratios were combined in a meta-analysis using restricted-maximum likelihood model. The square boxes represent the odds ratios (ORs) and the
lines the 95% confidence intervals (CIs). aEPIC-Italy corresponds to the new EPIC-Italy samples, not included in the development of the MI
Johansson et al. Clinical Epigenetics           (2019) 11:66 Page 8 of 12
as a mechanism for the association with DNA
methylation.
Individual associations between each of the 31 target
CpG sites and breast cancer risk were further examined in
the Generations Study (dataset 4). Four CpG sites located
nearest the genes CTNNA2, GRB10, RPH3AL, and TINCR
showed individual associations with breast cancer risk in a
multivariable model (P < 0.05, Additional file 2: Table S6)
and were also associated with breast cancer risk in matched
case-control pairs in EPIC-Italy (dataset 2).
Discussion
In this study, we have performed an EWAS of lifetime
estrogen exposure using the HM450K array and identi-
fied 694 CpG sites (FDR Q < 0.05) associated with ELEE
in the EPIC-Italy study cohort. In addition to this, we
have conducted a validation step in a case-control study
nested within a large independent cohort, the Genera-
tions Study, using targeted bisulfite sequencing. We have
developed a methylation index (MI) to predict ELEE
using DNA methylation levels at 31 CpG sites and tested
the MI for association with breast cancer risk. Although
the MI did not correlate with ELEE in the validation co-
horts, it was associated with breast cancer risk. Women
in the highest quartile of the MI in the Generations
Study had 77% higher risk for breast cancer compared
with women in the lowest quartile (Additional file 2:
Table S5). In the meta-analysis, including three other in-
dependent datasets, the highest quartile had a 45%
higher risk compared with the lowest quartile (Fig. 4).
There are several potential explanations why the cor-
relation between the MI and ELEE was only seen in the
discovery EPIC-Italy dataset and not in the additional
validation cohorts. Firstly, it is possible that the observed
association between MI and ELEE in EPIC-Italy is a false
positive and that the MI was over fitted in this study co-
hort. It may also be possible that the measured methyla-
tion index could capture the biological effects of
unknown confounders that are not included in the cal-
culated ELEE model. Alternatively, population-specific
differences between the cohorts (or between sub-cohorts
of EPIC-Italy) cannot be excluded. For example, there
are more smokers in the EPIC studies compared with
the Generations Study and MCCS, which considerably
affects DNA methylation. Also, there are different pat-
terns in breastfeeding, number of pregnancies, and OC
and HRT use across the studies, which may all affect the
total lifetime estrogen exposure and DNA methylation.
With the current evidence, we conclude that the methy-
lation index developed does not directly predict ELEE.
We observed no evidence for reverse causation with a
higher association between the MI and breast cancer risk
for cases with a longer time to diagnosis (Fig. 4). In the
meta-analysis, the association with breast cancer risk
was only significant for the cases with the time to diag-
nosis greater than the median in the continuous MI
model (OR = 1.05, 95% CI 1.01–1.10, P = 0.021, Additional
file 2: Table S8). More work is needed using longitudinal
studies to understand the dynamics of this MI over time.
In this study, we used an ELEE model based on a
woman’s age at recruitment (premenopausal women) or
age at menopause (postmenopausal women), age at me-
narche, number of pregnancies, and breastfeeding dur-
ation. The model does not include all the variables that
can affect estrogen exposure, for example, menstrual
cycle regularity, long-term pregnancies with miscarriage
or abortion as outcome, and current use of HRT or OC.
Hormonal risk factors are difficult to assess comprehen-
sively via questionnaires; for example, the short-term
outcome of being pregnant is increased estrogen levels
and breast cancer risk, but in the long term, the estrogen
levels and risk are reduced compared with nulliparous
women [9, 10, 45]. Subtracting 1 year for each pregnancy
instead of 9 months for each pregnancy did not materi-
ally change the results and might reflect the lifetime es-
trogen exposure better because there is a delay of 3
months on average before ovulatory cycling resumes.
OC and HRT use is associated with elevated risk in
current users, but it is not known how it will contribute
to the lifetime estrogen exposure or DNA methylation.
For this reason, we have not included OC and HRT use
in our ELEE model. Other hormonal exposures accom-
panied by estrogens, such as progesterones, were not
considered in this study. We acknowledge that the ELEE
model is not a perfect model for cumulative estrogen ex-
posure; however, it was hypothesized that if DNA methy-
lation signature could be identified as an intermediate
biological phenotype for the exposure, this might be more
accurate measurement than questionnaire-based estimates.
We acknowledge the small sample size of the dis-
covery EWAS in EPIC-Italy (n = 216) and potential
false positive hits due to artefactual inflation of test
statistics. We attempted to reduce the likelihood of
false positive associations by correcting for multiple
testing and restricting the MI signature to CpGs
showing the largest changes in DNA methylation.
Replication and validation are important steps to
identify valid DNA methylation biomarkers. For valid-
ation of the MI and breast cancer risk, we used an
independent method, targeted bisulfite sequencing, on
a case-control study nested within a large independ-
ent study cohort (the Generations Study, n = 880) and
a meta-analysis across four independent study cohorts
(n = 2374). Another limitation that we identified was
that not all 31 CpG sites are present on the updated
Illumina HumanMethylation EPIC (850K) array, which
precludes the possibility of including 850K studies in
this analysis without changing the model.
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Breast cancer risk assessment needs further improve-
ment to be able to identify women at low or high risk of
developing breast cancer that would warrant a preventive
intervention. It remains to be explored if epigenetic
signatures, in combination with other existing risk
models, polygenic risk scores and breast density mea-
surements, will improve breast cancer risk prediction
and stratification. Furthermore, blood sampling is an
accessible and less invasive method that is relatively
easy to include into population screening. Targeted
prevention approaches, including chemoprevention or
lifestyle changes, for high-risk women might reduce
the breast cancer incidence rate.
Conclusion
In this study, a DNA methylation signature in blood asso-
ciated with breast cancer risk was identified. However, the
methylation signature, although developed from ELEE as-
sociations in the EPIC-Italy cohort, was not associated
with lifetime estrogen exposure in the subsequent cohorts
A B
C
D
Fig. 4 Time to diagnosis and the association between the MI and breast cancer risk. Matched case-control pairs were stratified on median
time to diagnosis in EPIC-Italy HM450K data (dataset 2) and in the four study cohorts included in the meta-analysis. The association
between the MI and breast cancer risk was analyzed in the two groups. a The MI was significantly associated with breast cancer risk in
EPIC-Italy pairs with a shorter time to diagnosis (n = 81 pairs, OR = 1.47, 95% CI 1.12–1.93, P = 0.005). b The MI was significantly associated
with breast cancer risk in EPIC-Italy pairs with a longer time to diagnosis (n = 81 pairs, OR = 1.84, 95% CI 1.30–2.61, P = 0.001). c The
combined meta-analysis including pairs with shorter time to diagnosis showed no significant association between the MI and breast
cancer risk (OR = 1.03, 95% CI 0.98–1.08, P = 0.241). d The combined meta-analysis including pairs with shorter time to diagnosis showed
no significant association between the MI and breast cancer risk (OR = 1.05, 95% CI 1.01–1.10, P = 0.021). The log odds ratios were
combined in the meta-analyses using restricted-maximum likelihood model. ORs were adjusted for age, BMI, alcohol consumption, and
smoking duration (all variables reported at recruitment) and WBC composition
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analyzed. Further investigation is required to confirm the
interaction between estrogen exposure and DNA methyla-
tion in blood, and how epigenetic signatures might im-
prove risk assessment models.
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